Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

VIP (vasoactive intestinal peptide) regulatory status

Current status of VIP (vasoactive intestinal peptide) in the United States: In FDA review (Category 1). In sport: WADA status unclear. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of VIP (vasoactive intestinal peptide)?

Regulatory: In FDA review (Category 1)WADA: WADA status unclearVerified: Verified Sep 29, 2026
FDA and compounding
Not an FDA approved drug in the United States. An aviptadil and phentolamine combination is approved in some European countries for erectile dysfunction, and aviptadil was studied under FDA authorized COVID-19 trials but never authorized or approved. Vasoactive intestinal peptide appears on the FDA 503A bulk drug substances list as Category 1 (nominated and under evaluation), so under FDA's interim policy FDA does not intend to act against a state-licensed 503A pharmacy that compounds it on a prescription if the policy's conditions are met, until FDA decides by rule. That is not an approval. It has not been placed on the bulks list, was not part of the April 2026 Category 2 withdrawals, and was not among the peptides FDA presented to the committee in July 2026.
WADA
WADA status unclear
Access path
  1. Prescription from a licensed provider filled by a 503A compounding pharmacy as an intranasal spray, while VIP remains in FDA Category 1.
  2. Not available as an FDA approved product.
  3. Products labeled research use only are unapproved drugs when sold for human use and are not verified for purity.

Full VIP (vasoactive intestinal peptide) page: evidence, dosing in the literature, and sources

How has the status of VIP (vasoactive intestinal peptide) changed over time?

No dated regulatory event has been recorded for VIP (vasoactive intestinal peptide). That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for VIP (vasoactive intestinal peptide) and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  2. [2]FDA: 503A bulk drug substances category lists (PDF, updated 2026; vasoactive intestinal peptide listed in Category 1)FDA, 2026
  3. [3]WADA Prohibited ListWADA, 2026
  4. [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026